• Globus Medical (NYSE:GMED) has signaled plans to pursue additional acquisitions that complement its existing portfolio.
• The company also highlighted increased focus on product development and vertical integration as key uses of capital going forward.
• These priorities point to a mix of external deals and internal investment as Globus Medical shapes its next phase of growth.

Globus Medical, trading at $87.81, has seen its share price move 16.4% higher over the past year and 64.9% over the past 3 years. In that context, the company is indicating fresh interest in complementary M&A while continuing to put money into its own product pipeline and integrated manufacturing footprint.

For investors, the combination of targeted acquisitions and internal projects could influence how Globus Medical allocates cash and manages risk. How effectively NYSE:GMED balances deal making with product and vertical integration spending may be a key factor to watch over the coming years.

Stay updated on the most important news stories for Globus Medical by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Globus Medical.

This update gives you a clearer picture of how Globus Medical might use its balance sheet in the next phase. Management is signaling that the priority list starts with product development, inventory and field sets, and further vertical integration of manufacturing, with capital expenditure guided to 5% to 6% of net sales in 2026. Tuck in acquisitions are framed as complementary, not transformative, which points to a focus on adding specific technologies rather than pursuing very large deals. Against the backdrop of fourth quarter 2025 sales of US$826.42 million and full year sales of US$2.94b, as well as materially higher net income compared with the prior year, this mix of internal and external investment could matter for how you think about future margins and capacity. The reaffirmed 2026 revenue guidance range of US$3.18b to US$3.22b also provides a reference point for the scale of the business as it considers further M&A. For you as an investor, the key questions are whether smaller acquisitions can plug product gaps efficiently and whether vertical integration can support consistent profitability without stretching integration and execution too far.

How This Fits Into The Globus Medical Narrative

• The emphasis on product development, enabling technologies and vertical integration lines up with the narrative that robotics, navigation and broader offerings could support differentiation and margins over time.
• Ongoing M&A, including potential tuck in deals on top of prior acquisitions, could challenge the narrative if integration complexity or high costs start to weigh on earnings or disrupt sales momentum.
• The clear reference to continued share repurchases and incremental acquisitions is not fully captured in the narrative, which focuses more on operations, so buybacks and smaller deals could slightly change how capital deployment shapes future outcomes.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Globus Medical to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Integration execution across existing and potential future acquisitions could strain resources, especially in a competitive market that includes players like Medtronic and Johnson & Johnson.
• ⚠️ Higher ongoing capital spending and inventory investment could limit flexibility if returns on these projects or acquisitions do not match expectations.
• 🎁 Reaffirmed 2026 revenue guidance in the US$3.18b to US$3.22b range, alongside higher recent net income, indicates the business currently has the scale to support continued investment in its product and manufacturing base.
• 🎁 A focus on tuck in deals, rather than very large acquisitions, may help Globus Medical add targeted technologies while keeping balance sheet and integration risk more contained.

What To Watch Going Forward

From here, you may want to track how Globus Medical splits capital between internal projects, share repurchases and acquisitions, and whether that mix lines up with the earnings profile shown in the latest results. Progress on vertical integration, including any effect on gross margins, will be worth watching, as will commentary on how recent and future deals are performing relative to expectations. It can also help to compare Globus Medical’s capital allocation and product roadmap with other large spine and orthopedic device companies such as Stryker and Zimmer Biomet, especially as competition in robotics and enabling technologies continues to evolve.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Globus Medical, head to the community page for Globus Medical to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.